Patents Assigned to Janssen Pharmaceutica
-
Publication number: 20240124435Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.Type: ApplicationFiled: September 27, 2023Publication date: April 18, 2024Applicant: JANSSEN PHARMACEUTICA NVInventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
-
Patent number: 11958856Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: Pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: July 21, 2022Date of Patent: April 16, 2024Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Zhijie Liu
-
Publication number: 20240116930Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.Type: ApplicationFiled: October 18, 2023Publication date: April 11, 2024Applicant: JANSSEN PHARMACEUTICA NVInventors: Manuel Jesus ALCAZAR VACA, Jose Lgnacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
-
Publication number: 20240109910Abstract: The present invention is related to compounds of formula (I) and compounds of formula (II) and pharmaceutical composition thereof, useful as agonists of the CB1 and/or CB2 receptor(s).Type: ApplicationFiled: October 9, 2020Publication date: April 4, 2024Applicant: JANSSEN PHARMACEUTICA NVInventors: SANATH K MEEGALLA, Mark R. Player
-
Patent number: 11944605Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: November 25, 2020Date of Patent: April 2, 2024Assignee: Janssen Pharmaceutica NVInventors: Eddine Saiah, David John O'Neill, Seong Woo Anthony Kang
-
Patent number: 11939361Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.Type: GrantFiled: November 19, 2021Date of Patent: March 26, 2024Assignees: Janssen Pharmaceutica NV, Protagonist Therapeutics, Inc.Inventors: Giustino Di Pretoro, Dajun Sun, Gopal Rajan, Geraldine Broeckx, Nathalie Mertens, Shu Li, Felix Lai, Mohammad Masjedizadeh, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
-
Patent number: 11919881Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: March 17, 2022Date of Patent: March 5, 2024Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
-
Patent number: 11919870Abstract: Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3 and R4 are defined herein.Type: GrantFiled: October 31, 2022Date of Patent: March 5, 2024Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Pablo Garcia-Reynaga
-
Patent number: 11897880Abstract: The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: April 29, 2022Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Tianbao Lu, Zhijie Liu, Micheal D. Gaul
-
Patent number: 11897872Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.Type: GrantFiled: October 31, 2022Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
-
Patent number: 11897900Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: December 18, 2020Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 11891387Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.Type: GrantFiled: March 25, 2021Date of Patent: February 6, 2024Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
-
Patent number: 11883526Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.Type: GrantFiled: April 1, 2022Date of Patent: January 30, 2024Assignee: Janssen Pharmaceutica NVInventors: Jaskaran Singh, Ella Daly, Margaret Fedgchin, David Hough, Vanina Popova
-
Patent number: 11883367Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: March 9, 2022Date of Patent: January 30, 2024Assignee: Janssen Pharmaceutica NVInventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
-
Publication number: 20240021192Abstract: System and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in the subject based on a speech sample. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitive decline patients to generate an ensemble classifier comprising a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine-learning classifier configured to generate a component output identifying a sample data as corresponding to a normal patient or a cognitive patient. The machine-learning classifier is generated based on a subset of available features. The ensemble module receives component outputs from all of the component classifiers and generates an ensemble output identifying the sample data as corresponding to a normal or cognitive decline patient based on the component outputs.Type: ApplicationFiled: April 17, 2023Publication date: January 18, 2024Applicant: Janssen Pharmaceutica NVInventors: Srinivasan VAIRAVAN, Vaibhav NARAYAN
-
Patent number: 11872220Abstract: The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.Type: GrantFiled: August 8, 2022Date of Patent: January 16, 2024Assignee: Janssen Pharmaceutica NVInventors: Eric Frederik Eldering, Karoline Kielbassa, Ulrike Philippar, Andrew Steele, Marco Vincent Haselager, A. P. Kater
-
Patent number: 11873298Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.Type: GrantFiled: October 24, 2018Date of Patent: January 16, 2024Assignee: JANSSEN PHARMACEUTICA NVInventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
-
Publication number: 20230419850Abstract: Cognitive and mood states of a real world person are assessed according to activity in a virtual world environment with which the person interacts. The virtual world is configured to provide interactive experiences for assessing the person's cognitive and/or mood states. The system requires configuration of a session avatar during each virtual world session to provide then-current insight into the person's mood state. The system may require configuration of an avatar reflective of the person's state. The system requires the person to configure the virtual world environment during each virtual session to provide then-current insight into the person's mood state. The system permits the user to visit destinations, perform tasks and play games that are included in the environment for the purpose of providing insight into the person's cognitive and/or mood states according to the person's selections and/or performance.Type: ApplicationFiled: March 27, 2023Publication date: December 28, 2023Applicant: Janssen Pharmaceutica NVInventors: Joseph Barbuto, Katherine Bettencourt, Carine Brouillon, Gabriel Brun, Alexandra Kramer, Joe Manfredonia, Husseini Manji, Kenneth Mosca, Mark Sapp, Magdalena Schoeneich
-
Patent number: 11856084Abstract: Embodiments facilitate interoperability and secure determination of healthcare costs. An entity may receive a first Electronic Health Record (EHR) sub-block with patient medical coverage information and first treatments and may transmit a first Device Drug Information (DIR) sub-block comprising first treatment classes corresponding to each first treatment, first treatment class members corresponding to each first treatment class, and corresponding first treatment class member cost information. In response, the entity may receive a second EHR sub-block comprising second treatments each: associated with a corresponding first treatment, and selected from corresponding first treatment class members. Upon receipt of a transaction confirmation, the entity may augment a multi-dimensional blockchain with a multi-dimensional block formed by linking: a DIR block including second treatment information, an EHR block including information based on the second EHR sub-block and a transaction block.Type: GrantFiled: December 15, 2022Date of Patent: December 26, 2023Assignee: Janssen Pharmaceutica NVInventors: Jessica Lee, Jun Morimura, Michael Moschetti, John Vig, Marvin Quesada, Andrew Thomson
-
Patent number: D1015139Type: GrantFiled: March 9, 2023Date of Patent: February 20, 2024Assignee: Janssen Pharmaceutica NVInventors: Michael Cannamela, Emma Hubert